Seattle Genetics Completes Enrollment in SGN-33 Trial
Luke Timmerman2/25/09
Seattle Genetics, the Bothell, WA-based developer of targeted cancer drugs, said today it had completed enrollment in a trial of 210 patients with acute myeloid leukemia. The study is looking at the company’s SGN-33 drug in combination with a low-dose chemotherapy drug, compared with the chemotherapy drug alone. The main goal of the study is to help people live longer. Seattle Genetics (NASDAQ: SGEN) expects to see results by the first half of 2010.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
